Moving from indication to transplantation is a critical process in myelofibrosis. Most of
guidelines specifically focus on either myelofibrosis disease or transplant procedure, and …

Background Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the
only curative treatment for patients with myelofibrosis (MF). Transplant related mortality …

Primary or post-ET/PV myelofibrosis is one of the Philadelphia-negative myeloproliferative
neoplasms with worst survival. Allogeneic stem cell transplantation (ASCT) can cure a …

New available drugs allow better control of systemic symptoms associated with
myelofibrosis (MF) and splenomegaly but they do not modify the natural history of …

Advances in understanding the pathogenesis and molecular landscape of myelofibrosis
have occurred over the last decade. Treating physicians now have access to an ever …

The aim of this review is to update the current status of allogeneic hemopoietic stem cell
transplants (HSCT) for patients with myelofibrosis (MF). We have first summarized the issue …

Myelofibrosis is one of the classical Philadelphia chromosome–negative myeloproliferative
neoplasms characterized by progressive marrow failure and chronic inflammation …

Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative
therapeutic modality for patients with primary or secondary myelofibrosis (MF). However …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

The aim of this work is to produce recommendations on the management of allogeneic stem
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …